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Abstract
New antiretroviral drugs that offer large genetic barriers to resistance, such as the recently approved inhibitors of HIV-1
protease, tipranavir and darunavir, present promising weapons to avert the failure of current therapies for HIV infection.
Optimal treatment strategies with the new drugs, however, are yet to be established. A key limitation is the poor
understanding of the process by which HIV surmounts large genetic barriers to resistance. Extant models of HIV dynamics
are predicated on the predominance of deterministic forces underlying the emergence of resistant genomes. In contrast,
stochastic forces may dominate, especially when the genetic barrier is large, and delay the emergence of resistant genomes.
We develop a mathematical model of HIV dynamics under the influence of an antiretroviral drug to predict the waiting time
for the emergence of genomes that carry the requisite mutations to overcome the genetic barrier of the drug. We apply our
model to describe the development of resistance to tipranavir in in vitro serial passage experiments. Model predictions of
the times of emergence of different mutant genomes with increasing resistance to tipranavir are in quantitative agreement
with experiments, indicating that our model captures the dynamics of the development of resistance to antiretroviral drugs
accurately. Further, model predictions provide insights into the influence of underlying evolutionary processes such as
recombination on the development of resistance, and suggest guidelines for drug design: drugs that offer large genetic
barriers to resistance with resistance sites tightly localized on the viral genome and exhibiting positive epistatic interactions
maximally inhibit the emergence of resistant genomes.
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Introduction
Current antiretroviral therapies for HIV infection often fail to
elicit lasting virological responses in patients because of the
emergence of multidrug resistant strains of HIV [1,2]. The
enormous replication rate and the high mutation and recombina-
tion rates of HIV [3–7] propel the acquisition of mutations that
confer upon HIV resistance to administered drugs. The same
mutations are often responsible for resistance to multiple drugs
belonging to a given drug class [1,2]. Consequently, treatment
options for patients who experience failure of therapy are
restricted [8,9]. The newly approved protease inhibitors (PIs),
tipranavir and darunavir, offer large genetic barriers to resistance
[10,11]. The genetic barrier of a drug, n, is the number of
mutations that HIV must accumulate to gain high level resistance
to the drug [12]. When n is small (e.g., n=1 for 3TC [1]), drug
resistant genomes are likely to exist in patients prior to the onset of
therapy [13]. As n increases, the likelihood of the pre-existence of
resistant genomes decreases considerably [13,14]. Resistant
genomes must then emerge during therapy through mutation
and/or recombination of susceptible genomes. The replication of
susceptible genomes, however, is suppressed during therapy.
Besides, HIV must undergo a large number of replication cycles
to accumulate all the mutations required for resistance to a drug
with large n. Consequently, the development of resistance to a
drug with large n may be significantly delayed. Indeed, up to
9 months were required for HIV to develop resistance to
tipranavir in in vitro serial passage experiments [10].
Current treatment guidelines for HIV infection recommend a
combination of 3, but at least 2, active drugs, (i.e., drugs for which
resistance has not developed) in order partly to increase the overall
genetic barrier of therapy [9]. For treatment naı ¨ve patients, a
combination of 2 nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs) is typically employed in combination with
either a non-nucleoside reverse transcriptase inhibitor (NNRTI),
usually efavirenz, or a ritonavir-boosted PI, usually lopinavir [9].
With ritonavir-boosted lopinavir monotherapy, fewer patients
achieved plasma HIV RNA levels below detection and more
patients witnessed emergence of PI resistance mutations than in
patients receiving ritonavir-boosted lopinavir in combination with
2 NRTIs [15]. Similarly, despite comparable times to virological
failure, patients receiving a 2 drug combination of efavirenz and
lopinavir experienced more frequent emergence of resistance than
patients receiving a 3 drug combination of efavirenz or lopinavir
and 2 NRTIs [16]. Therapy with 4 NRTIs had a similar response
to therapy with efavirenz and 2 NRTIs [17]. Consequently, a 3
drug combination is the current standard of care for treatment
naı ¨ve patients. When failure did occur with a 3 drug combination,
it was typically associated with NNRTI resistance in patients
receiving efavirenz but not with PI resistance in patients receiving
lopinavir [16], in accordance with the larger genetic barriers
offered by PIs than by NNRTIs [18]. The large genetic barrier in
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underlie the high rates of viral suppression despite sub-optimal
adherence in patients receiving ritonavir-boosted lopinavir-based
therapy [19].
For second-line therapy, which follows the failure of the initial
regimen, a drug from a new drug class is recommended in order to
minimize the risk of cross-resistance [9]. Thus, among several
newly available agents [20], the fusion inhibitor enfuvirtide and
the recently approved integrase inhibitor raltegravir present potent
options. Both enfuvirtide and raltegravir, however, offer small
genetic barriers and are therefore recommended for use in
conjunction with a supporting drug such as darunavir [9].
Remarkably, the new PIs, tipranavir and darunavir, elicit
responses against viral strains resistant to other PIs [11,21],
increasing options for second-line therapy. The new PIs thus
present promising weapons to avert the failure of antiretroviral
therapy. Indeed, significant efforts are ongoing to identify
treatment protocols that maximize the impact of the new PIs
[8,22]. Identification of improved protocols hinges on our
understanding of HIV dynamics under the influence of drugs
that offer large genetic barriers to resistance and of the process by
which HIV surmounts these large genetic barriers.
Description of the development of resistance to a drug with a
large n is complicated for several reasons. First, resistance to such a
drug typically develops gradually, increasing progressively with the
number of mutations accumulated [10,23]. As a result, the
emergence and the competitive dynamics of a large number of
distinct viral genomes carrying different combinations of resistance
mutations and possessing various intermediate levels of resistance
must be described. For instance, the accumulation of mutations at 6
loci confers high level resistance to tipranavir [10]. Consequently,
depending on whether each resistance locus carries a mutation or
not, 2
6, or 64, distinct strains (see below) may emerge in the course
of infection. Because HIV is diploid, the 64 strains yield 64
homozygous and 2016 different kinds of heterozygous virions,
whose evolutionary dynamics must be followed to describe how the
genetic barrier of tipranavir is overcome. Second, the population
size of HIV in vivo may be small, especially under the influence of
therapy, which implies that the emergence of resistant genomes is
likely to be governed by stochastic rather than deterministic effects
[24]. Third, in addition to mutation, recombination can play a
significant role in the formation of drug resistant strains that carry
multiple mutations [25,26]. The influence of recombination, which
is yet to be fully understood, depends on several factors, viz., the
frequency of multiple infections of cells, the effective population size
of HIV in vivo, and the nature of fitness interactions between
resistance mutations, characterized by epistasis [27–33]. No models
exist that describe HIV dynamics under the simultaneous influence
of mutation, multiple infections of cells, recombination, epistatic
interactions between multiple resistance mutations, and stochastic
effects of finite population sizes. Consequently, timing the failure of
antiretroviral drugs with large genetic barriers is currently not
possible. Rational identification of improved treatment protocols is
therefore precluded.
Here, we develop a model of HIV dynamics that quantitatively
predicts the expected waiting time for the emergence of genomes
that carry the requisite mutations for resistance to a drug with any
given genetic barrier. Extant models of HIV dynamics assume that
deterministic forces are predominant in the emergence of drug
resistance [34–36]. Consequently, extant models predict that drug
resistant genomes emerge immediately upon the initiation of
therapy, albeit in small numbers. In contrast, especially when the
genetic barrier is large, stochastic forces are expected to dictate the
emergence of resistant genomes. A key consequence of the
predominance of stochastic forces is a delay in the emergence of
resistant genomes following the initiation of therapy. Our model
accounts for this delay in a deterministic manner by predicting the
expected waiting time for the emergence of resistant genomes.
Model predictions capture the development of resistance to
tipranavir in vitro quantitatively, indicating that our model captures
the underlying dynamics of the development of resistance to
antiretroviral drugs. Further, model predictions provide insights
into the impact of underlying evolutionary forces on the develop-
ment of drug resistance and suggest guidelines for drug design.
Results
Model Formulation
We consider uninfected cells, T, exposed in the presence of a PI
with a genetic barrier n to a viral population, V, containing genomes
highly susceptible to the PI. The highly susceptible, or wild-type,
genomes are assumed to contain no resistance mutations. As
infection proceeds, error-prone replication gives rise to mutant
genomes. S~2n{1 distinctmutantgenomes canarise, each with at
least one resistance mutation (Figure 1). Our aim is to determine the
waiting time for the first formation of the genome that carries all the
n resistance mutations and is therefore highly resistant to the drug.
We number the different viralgenomes 0,1, 2, 3…S, where genome
0 represents the wild-type (Figure 1). We let Vjh denote the
population of virions containing genomes j and h, where j, h M {0, 1,
2…S}. Because virions V10, for instance, are indistinguishable from
virions V01, we impose the constraint j#h [37]. Following the
infection of a cell by a virion Vjh, mutation and recombination give
rise to a proviral genome i M {0, 1, 2…S} with probability Qi(jh). We
distinguish infected cells by the proviral genomes they contain: Cells
Ti are infected by a single provirus i and cells Tij by proviruses i and
j, where i#j and i, j M {0, 1, 2…S}. Infected cells produce progeny
virions. Drug action causes some of the progeny virions to be non-
infectious [3,34,35]; we denote the noninfectious virion population
by VNjh. Cells Ti and Tii infected by a single kind of provirus
produce homozygous virions Vii and VNii. Cells Tij infected with
distinct proviruses (i?j) yield homozygous virions Vii, VNii, Vjj and
Author Summary
The ability of HIV to rapidly acquire mutations responsible
for resistance to administered drugs underlies the failure of
current antiretroviral therapies for HIV infection. The recent
advent of drugs that offer large genetic barriers to
resistance, e.g., tipranavir and darunavir, presents a new
opportunity to devise therapies that remain efficacious
over extended durations. The large number of mutations
that HIV must accumulate for resistance to drugs with
large genetic barriers impedes the failure of therapy.
Further, these drugs appear to exhibit activity against viral
strains resistant to other drugs in the same drug class,
thereby significantly improving options for therapy.
Rational identification of treatment protocols that maxi-
mize the impact of these new drugs requires a quantitative
understanding of the process whereby HIV overcomes
large genetic barriers to resistance. We develop a model
that describes HIV dynamics under the influence of a drug
that offers a large genetic barrier to resistance and predict
the time of emergence of viral strains that overcome the
large barrier. Model predictions provide insights into the
roles of various evolutionary forces underlying the
development of resistance, quantitatively describe the
development of resistance to tipranavir in vitro, and
suggest guidelines for drug design.
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network is shown in part in Figure 2.
We construct dynamical equations to predict the time-evolution
of various cell and viral populations and estimate the average
waiting times for the first production of each of the S mutant
proviral genomes (Methods). We denote by W the waiting time for
the emergence of the provirus that contains all the n resistance
mutations and hence overcomes the genetic barrier of the drug.
Model Predictions
We solve model equations to describe the development of
resistance in in vitro serial passage experiments (e.g., [10]). Here, T0
uninfected cells are exposed to viruses in the presence of a known
concentration of the PI. Infection is allowed to progress until time
tp (,3.5 days), the duration of a passage. The resulting viral
population is employed to initiate infection of a fresh set of T0
uninfected cells in the next passage. At the start of the first passage,
the viral population is assumed to consist of V00 wild type viruses,
highly susceptible to the drug. Gradually, genomes with increasing
levels of drug resistance emerge.
Cell and virus dynamics. We perform calculations for a
genetic barrier n=5, representative of ritonavir-boosted PIs [38].
We let the separation between successive resistance mutations,
l=100 nucleotides, and choose the efficacy profile shown in
Figure 3 with epistasis E=0 (also see Methods). Here, the efficacy
against the wild type, e0, and against the strain with n mutations,
en, correspond to 400 nM of tipranavir [10]. We assume that the
efficacy against intermediate mutants, em, depends on the number
of mutations, m (0#m#n), the genomes contain. In Figure 4A, we
present the evolution of populations of uninfected cells, T, infected
cells, T ~
P S
i~0
Tiz
P S
i~0
P S
j~i
Tij, and infectious virions,
V~
P S
i~0
P S
j~i
Vij, with time following the onset of the experiment.
In the first passage, T rises due to the proliferation of uninfected
cells (Figure 4A, inset). At the same time, T
* rises due to the
infection of T, and V rises sharply due to viral production from T
*.
In the second passage, the higher V enhances the infection of T.
Here, the loss of T due to infection dominates cell proliferation
and T declines. Consequently, following an initial rise of T
* due to
infection of T, target cell limitation lowers the formation of new
infected cells and causes T
* to decline. The resulting lower viral
production causes V to decline as well. This two phase behavior
within a passage–an initial rise and the subsequent fall of T
*–is
observed in experiments [7] and is explained by models [37,39].
The same two phase behavior repeats in ensuing passages and an
oscillatory pseudo steady state is attained. Gradually, V rises
marking the emergence of drug resistant genomes.
Emergence of resistant genomes. In Figure 4B, we present
the time-evolution of populations of infectious homozygous virions
containing genomes with different numbers of resistance mutations.
Initially, the viral population contains the wild type genomes alone.
Following the onset of infection, as V rises, the rate of formation of
single mutants increases. Single mutants emerge here in the first
passage. Because drug efficacy is lower against single mutants than
against wild type genomes (e1,e0; Figure 3), single mutants begin to
grow at the expense of the wild type. (We note that unlike the
scenario in vivo, passage experiments are designed to allow the
growth of even wild-type genomes in the initial passages.) As
infections by single mutants become significant, the rate of
formation of double mutants rises. Double mutants emerge in
,40 days. With n=5,
5
2
  
~10 different double mutants are
possible. They emerge at slightly different times because of the
differential influence of recombination: A double mutant that
contains the two mutations on adjacent resistance loci is less likely to
be formed by recombination than a double mutant with mutations
on well separated loci; the number of crossovers increases with the
separation [40]. Again, because e2,e1,e0 (Figure 3), double
mutants begin to outgrow single mutants and the wild type. This
process continues with the sequential emergence of higher mutants
until by W,100 days quintuple mutants emerge, which possess
high level resistance to the drug. W,100 days is thus the waiting
time for the emergence of the genome that overcomes the genetic
barrier of the drug. From this point on,quintuple mutants dominate
the viral population.
Several characteristics of drugs, viz., the genetic barrier, n,
epistasis, E, and the separation between adjacent resistance loci, l,
influence W, which we examine next.
Effect of the genetic barrier. To examine the influence of
the genetic barrier, we vary n for fixed values of e0, en, and E, and
predict W. We find that W increases dramatically with n. For
instance, W increases from ,12 days when n=2 to ,100 days
when n=5 (Figure 5A), underscoring the advantage of a drug with
a large n.A sn increases, the number of mutations necessary for
resistance increases. The number of replication cycles required to
accumulate the necessary mutations increases correspondingly and
Figure 1. Schematic representation of the S viral genomes
carrying different combinations of resistance mutations (stars)
that emerge during the development of resistance to a drug
with a genetic barrier n.
doi:10.1371/journal.pcbi.1000305.g001
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resistance is inhibited further by the delayed emergence of
intermediate mutants. For the same e0 and en, the incremental
fitness advantage with each mutation decreases as n increases. The
smaller this advantage, the longer it takes for the resolution of the
competition between different mutants. Thus, following their
emergence, double mutants take longer to outgrow single mutants
when n=4 than when n=3. When the influence of recombination
is weak, triple mutants emerge predominantly by mutation of
double mutants. Consequently, the waiting time for the emergence
of triple mutants is larger when n=4 than when n=3. Indeed,
triple mutants emerge in ,40 days when n=3 and ,55 days
when n=4 (Figure 5A). Thus, the increasing number of replication
cycles required and the slower emergence of intermediate mutants
together result in the dramatic increase of W with n.
Effect of epistasis. The increase of W with n is amplified
when E.0. Whereas W increases from ,12 to ,100 days when
E=0,W increases from ,12 to ,205 days when E=0.005 as n
increases from 2 to 5 (Figure 5B). As E increases, the fitness of
intermediate mutants decreases (Figure 3). Consequently,
intermediate mutants emerge slower, increasing W (Figures S1
and 5B). In contrast, the fitness of intermediate mutants is higher
(Figure 3) and hence the increase of W with n is suppressed when
E,0 (Figures S1 and 5B).
Effect of recombination. Interestingly, recombination
decreases W regardless of E (Figure 5C). Recombination
accelerates the accumulation of mutations and expedites the
emergence of resistant strains. Thus, upon increasing the
recombination rate, which we accomplish by increasing l,t h e
separation between resistance loci, W drops by ,50% when
E=0.005 and by ,80% when E=20.005 for n=5 from that in
the absence of recombination (Figure 5C, inset). The greater drop in
W when E,0 is because of the increased fitness (Figure 3) and hence
greater prevalence of intermediate mutants, which in turn enhances
the likelihood of the formation of heterozygous virions and facilitates
the accumulation of mutations by recombination. This influence of
recombination on W is robust to changes in n (Figure S2).
That recombination invariably lowers W is intriguing given that
several studies argue that recombination may inhibit the fixation of
resistance when E.0 (e.g., see [27,33]). We therefore compute the
fixation time, F, defined as the time when 90% of the genomes in the
viral population are n
th mutants. We find interestingly that
recombination increases F when E.0, consistent with current
expectations (Figure 5D) [27,33]. When n=2, W marks the time
when the first double mutant emerges in the viral population. For
timessmallerthanW,t h ew il d - t y p ea n dt h esi n g lem u t a n t sa l o n ee x i st
in the viral population. Recombination then brings the mutations on
the two single mutants together and accelerates the emergence of the
double mutant regardless of E. After the double mutant emerges,
recombination influences the competitive dynamics of the different
Figure 3. Efficacy, em, of a genome carrying m (0#m#n)
resistance mutations, when the genetic barrier n=5, e0=0.85,
en=0.25, and the epistasis, E=0.005 (green), 0 (red), and
20.005 (blue). The inset shows the corresponding fitness (=12em)
profiles.
doi:10.1371/journal.pcbi.1000305.g003
Figure 2. Schematic representation of the infection network indicating the various singly and doubly infected cells, Ti and Tij, and
homozygous and heterozygous virions, Vii and Vij, respectively, that emerge during the development of drug resistance. Non-
infectious virions are crossed.
doi:10.1371/journal.pcbi.1000305.g002
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recombine to yield the double mutant, but the double mutant could
also be lost by recombination with the wild type. When E.0,
recombination tends to lower the prevalence of the double mutant
[27], resulting in the observed increase in F. Thus, recombination
may lower W and yet increase F. We note that the distinction
between emergence and fixation has been recognized earlier [41].
When E,0, recombination enhances the prevalence of the double
mutant and decreases F. We recognize here that the influence of
recombination on F is determined not only by E but also by n, e0, en,
and the population size of HIV and its variation, examining all of
which is beyond the scope of the present study. Our aim here is to
predict W, which marks the emergence of drug resistant genomes.
Comparison with Experiments
We apply our model to describe the development of resistance
to tipranavir in in vitro serial passage experiments [10]. We let n=6
because a genome with 6 resistance mutations exhibited .10 fold
resistance to tipranavir in these experiments. We choose IC50
values for different intermediate mutants from the ranges
determined experimentally (Table S1). Further, we employ actual
distances between resistance sites to calculate the recombination
probabilities and also assign fitness advantages to genomes
containing specific combinations of mutations (Table S1). (In
contrast, in our calculations above, the number of mutations and
not their specific combinations was assumed to determine the
fitness advantage.) We also vary the concentration of tipranavir as
in the experiments (Table S2). Further, following the experimental
protocol, we employ 90% of the viral population at the end of any
passage to initiate infection in the succeeding passage when the
drug concentration is maintained constant across the passages and
50% of the viral population when the drug concentration is
increased in the succeeding passage. Genomes carrying 2, 3, 5 and
6 resistance mutations were first observed in the experiment in
passages 16, 33, 39 and 49, respectively [10]. In close agreement,
our model predicts the emergence of these genomes in passages
14, 29, 44 and 49, respectively (Figure 6). (Ignoring the concept of
the waiting time, i.e., letting wi=0 in our model, severely
underpredicts the times of emergence of drug resistant genomes
(Figure 6). The agreement between model predictions and
experiments indicates that our model captures the underlying
dynamics of the development of resistance to antiretroviral drugs
accurately.
Discussion
Current models of HIV dynamics successfully predict short-
term changes in the plasma viral load in patients undergoing
therapy but fail to provide a quantitative description of the
emergence of drug resistance [34–36]. A key limitation of current
models is the underlying assumption that the emergence of
resistant genomes is governed by deterministic effects. Determin-
istic effects predominate when the population of cells in an infected
individual is large. In a finite cell population, because the
probability of the formation of a resistant genome with many
mutations can be small, resistant genomes emerge stochastically.
The waiting time for the emergence of resistant genomes can
therefore be substantial. In contrast, by assuming that determin-
istic effects predominate, current models predict that resistant
genomes emerge, albeit in very small numbers, immediately upon
the onset of therapy. Once resistant genomes emerge, their
numbers grow due to viral production from the cells they infect
leading to the rapid fixation of resistance. Current models thus
underestimate the time for the development of drug resistance
(Figure 6).
Simulations of viral evolution, based on models of population
genetics, consider finite populations and present descriptions of the
stochastic emergence of drug resistant genomes [28,29,32].
Importantly, the simulations also enable incorporation of recom-
bination and fitness interactions between multiple loci, which are
central to the development of drug resistance but are not easily
incorporated in models of HIV dynamics. The simulations,
however, make several simplifying assumptions, such as fixed
population sizes and discrete generations, which approximate the
dynamics of the development of drug resistance and introduce
uncertainties in the influence of underlying processes, such as
recombination [30,33]. Besides, simulations are difficult to
incorporate in mathematical formalisms for therapy optimization.
Figure 4. Model predictions of cell and viral dynamics. The time
evolution of (A) the number of uninfected cells (red), infected cells
(blue), and infectious virions (green) and (B) homozygous virions
carrying wild-type genomes (pink) and single (blue), double (green),
triple (orange), quadruple (red), and quintuple (black) mutants,
obtained by solving Eqs. (1)–(9) with the parameters T0=10
6 cells,
V00=5 610
5 virions, n=5,l=100 nucleotides, and em from Figure 3 with
E=0. The remaining parameters are listed in Methods. The inset in (A)
shows the evolution for the first two passages.
doi:10.1371/journal.pcbi.1000305.g004
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framework of models of HIV dynamics and at the same time
captures the influence of stochastic effects associated with the
emergence of drug resistant genomes. To accomplish this, we
invoke the concept of the expected waiting time. We develop a
detailed description of mutation and recombination between
multiple loci, which enables calculation of the probability of the
formation of resistant genomes in one replication event. Given the
viral and cell populations and the efficacy of the drug, the
frequency of replication events and hence the rate of formation of
resistant genomes is determined. From the rate of formation, we
estimate the expected waiting time for the first resistant genome to
emerge. Different mutant genomes are assumed to appear first in
the viral population at their respective expected waiting times. The
limitation of current models of HIV dynamics, which predict the
emergence of resistant genomes immediately upon the start of
therapy, is thus overcome. Yet, by calculating the ‘‘expected’’
waiting time, our model captures the influence of stochastic effects
associated with the emergence of resistant genomes in an averaged
sense and retains the dynamical framework of current models. The
limitations of population genetics based simulations are also thus
overcome.
The waiting time for the emergence of a genome carrying a
certain number of mutations depends on the times of emergence
and the growth of subpopulations of genomes with fewer
mutations. Our model assumes that the latter genomes emerge
at their expected waiting times. Consequently, the variation in the
waiting times for the emergence of higher mutants due to the
variation in the times of emergence of lower mutants is suppressed
in our model. Further, following emergence, particularly when the
population size is small, the chance that stochastic forces cause the
extinction of genomes may be significant. We assume, however,
that following emergence, the growth of genomes is deterministic.
The extent of the uncertainties introduced in our model
predictions by these simplifying assumptions remains to be
estimated. Semi-stochastic simulations, where the times of
emergence of mutant genomes alone are determined stochastical-
ly, and fully stochastic simulations (see, e.g., [42]) of the emergence
Figure 5. Model predictions of emergence and fixation times. The expected waiting time for the emergence of (A) genomes with different
numbers of resistance mutations for different n when E=0, (B) the corresponding n
th mutants as a function of E, (C) quintuple mutants when n=5as
a function of the crossover frequency (rl), for E=0.005 (green), 0 (red), 20.005 (blue). The inset in (C) shows the corresponding reduction in the time
of emergence, 12W(rl)/W(rl=0). (D) Model predictions of emergence (filled symbols) and fixation (open symbols) times of double mutants when
n=2 and E=0.05 (green), 0 (red), 20.05 (blue). In (A) to (C), we let e0=0.85 and en=0.25, whereas in (D) e0=0.1 and en=0. All the other parameters
are identical to those in Figure 4.
doi:10.1371/journal.pcbi.1000305.g005
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the simulations, however, is beyond the scope of the present study.
Here, we compare model predictions with experiments and find
that our predictions are in close agreement with experimental
observations [10] of the times of emergence of various genomes
possessing different degrees of resistance to tipranavir, suggesting
that our model captures the underlying dynamics of the
development of drug resistance by HIV.
Model predictions indicate that the waiting time, W, for the
emergence of the strain that overcomes the genetic barrier of a
drug depends on several factors that may be tuned during drug
design. A large genetic barrier significantly enhances W. This
enhancement of W with the genetic barrier is amplified when
fitness interactions between resistance loci exhibit positive epistasis.
Recombination, in contrast, lowers W regardless of epistasis or the
genetic barrier. If the separation between resistance loci is small,
however, the role of recombination is suppressed. Thus, for
delaying the emergence of resistant genomes, drugs that offer large
genetic barriers with resistance sites localized tightly on the viral
genome and exhibiting positive epistatic interactions are desirable.
These observations may serve as guidelines for structure-based
drug design [43]. The fixation of resistant genomes following their
emergence may depend differently on drug characteristics and
remains to be fully elucidated.
When distinctions between different viral genomes are ignored,
the expected waiting time vanishes and our model reduces to the
basic model of HIV dynamics, which successfully captures viral
load changes in patients undergoing therapy [3,34]. Our model
may thus be applied to predict drug failure in vivo. Several
advances of our model are essential, however, to describe the in
vivo scenario accurately. First, the higher frequency of multiple
infections [44], possible cell-cell transmission of infection [45,46],
and the existence of resistance mutations prior to the onset of
therapy [1] in vivo must be incorporated into our model. Second,
during potent drug therapy, viral replication may be suppressed
significantly, resulting in a small effective population size of HIV.
The variation of the waiting time about the mean may then
become large. Consequently, the assumption that mutant genomes
emerge at their expected waiting times becomes less accurate. Our
model must therefore be advanced to account for the variation of
the emergence times of genomes in vivo. Third, our model must be
extended to drugs from other drug classes to mimic current
combination therapies. With these advances, our model would
enable timing the emergence of resistance to drugs in vivo and
facilitate the identification of treatment protocols that maximally
impede the failure of current therapies.
Methods
Dynamical Equations
We present equations below that describe the in vitro dynamics
of various cell and viral populations.
Uninfected cells.
dT
dt
~ l{dT ðÞ T{k0T
X S
i~0
Hw i ðÞ
X S
j~0
X S
h~j
Qi jh ðÞ Vjh ð1Þ
Uninfected cells, T, proliferate at rate l and die at rate dT. The
rate of formation of infected cells Ti containing genome i is
k0TH wi ðÞ
P S
j~0
P S
h~j
Qi jh ðÞ Vjh (see below). Summation over i from 0
to S=2
n21 yields the total rate of loss of T due to infection by free
virions. At the beginning of each passage, T is set to T0=10
6.
Singly infected cells.
dTi
dt
~Hw i ðÞ k0T
X S
j~0
X S
h~j
Qi jh ðÞ Vjh
{k1Ti
P i{1
k~0
Hw ki ðÞ
P S
j~0
P S
h~j
Qk jh ðÞ Vjh
z
P S
k~i
Hw ik ðÞ
P S
j~0
P S
h~j
Qk jh ðÞ Vjh
2
6 6 6 6 4
3
7 7 7 7 5
{dTi
ð2Þ
where i M {0, 1, 2…S}. Here, k0TVjh is the rate at which virions Vjh
infect T. Following infection, the genomes j and h undergo reverse
transcription to produce provirus i with the probability Qi(jh) (see
below). Thus, k0TQi(jh)Vjh is the rate at which uninfected cells
acquire genome i following infection by Vjh. Summation over j and
h yields the total rate, rTi~k0T
P S
j~0
P S
h~j
Qi jh ðÞ Vjh, of the
production of cells Ti.
The rate rTi can be small, especially if genome i contains many
mutations. Consequently, when the cell population is finite, the
formation of the first cell Ti is stochastic. We define ti as the
waiting time for the formation of the first cell Ti. ti may assume any
value between 0 and ‘ with a probability density dependent on
rTi t ðÞ(see below). Here, we assume as a simplification that the first
cell Ti emerges at the expected waiting time wi~StiT. In addition,
we assume that following emergence, the growth of Ti is
deterministic. We therefore multiply the rate rTi in Eq. (2) with
the Heaviside function,
Figure 6. Comparison of model predictions (red) and the
experimentally observed [10] (blue) times of emergence of
different mutants resistant to tipranavir. The different mutants
and the corresponding IC50 values are listed in Table S1. Also shown are
the times when the numbers of the different mutant proviruses first
reach 1 (green) predicted by our model when, following current models
[34,35], we assume that the waiting times wi=0.
doi:10.1371/journal.pcbi.1000305.g006
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0 tvwi
1 t§wi
 
ð3Þ
so that Ti=0 when t,wi, and cells Ti are produced at the rate rTi
when t$wi. By allowing Ti to grow at the rate rTi from time t=0,
extant models of HIV dynamics underestimate the time of
emergence of drug resistant genomes. We derive estimates of wi
below. We solve Eq. (2) with the initial condition, Ti(wi)=1, and
reset Ti to zero at the start of every passage. The other two terms
in Eq. (2) represent the loss of cells Ti due to death at rate d and
due to further infections, which convert Ti to doubly infected cells.
Doubly infected cells.
dTii
dt
~Hw ii ðÞ k1Ti
X S
j~0
X S
h~j
Qi jh ðÞ Vjh{dTii ð4aÞ
Here k1Ti
P S
j~0
P S
h~j
Qi jh ðÞ Vjh is the rate at which cells Ti acquire a
second provirus i. wii is the expected waiting time for the
emergence of the first cell Tii. After the first infection of a cell,
down-modulation of cell surface CD4 receptors reduces the
susceptibility of the cell to new infections [47,48]. Here, we let
k1(,k0) be the mean rate constant for the infection of singly
infected cells [37].
For cells infected with two different kinds of proviruses, we write
dTij
dt
~Hw ij
  
k1
Ti
P S
k~0
P S
h~k
Qj kh ðÞ Vkh
zTj
P S
k~0
P S
h~k
Qi kh ðÞ Vkh
2
6 6 6 4
3
7 7 7 5
{dTij ð4bÞ
where i,j and i, j M {0, 1, 2…S}. Here, the two terms in the
brackets correspond to the two ways of forming a doubly infected
cell Tij: a cell Ti can be infected by provirus j or a cell Tj by
provirus i. Following earlier studies, we ignore more than two
infections of cells [37]. We solve the above equations with the
initial conditions Tii(wii)=1 and Tij(wij)=1, respectively, and reset
Tii and Tij to zero at the start of every passage.
Waiting time: At any time t, the rate of formation of cells Ti,
rTi t ðÞ ~k0Tt ðÞ
X S
j~0
X S
h~j
Qi jh ðÞ Vjh t ðÞ : ð5Þ
Because individual infection events occur independently, the
formation of Ti may be described as a Poisson process with the
instantaneous rate rTi t ðÞ . The probability that the waiting time, ti,
for the first formation of a cell Ti is smaller than s is then
Pt iƒs ðÞ ~1{exp {
Ð s
0
rTi t ðÞ dt
 !
,0 #s,‘ [49]. It follows that
the expected waiting time, wi~StiT~
Ð ?
0
s LP
Ls,o r
wi~{
ð ?
0
s
L
Ls
exp {
ð s
0
rTi t ðÞ dt
0
@
1
A
0
@
1
Ads: ð6Þ
Similarly,
wij~{
ð ?
0
s
L
Ls
exp {
ð s
0
rTij t ðÞ dt
0
@
1
A
0
@
1
Ads, ð7Þ
where rTii t ðÞ ~k1Ti t ðÞ
P S
j~0
P S
h~j
Qi jh ðÞ Vjh t ðÞ and when i,j,
rTij t ðÞ ~k1 Ti t ðÞ
P S
k~0
P S
h~k
Qj kh ðÞ Vkh t ðÞ zTj t ðÞ
P S
k~0
P S
h~k
Qi kh ðÞ Vkh
 
t ðÞ   .
We recognize that the evaluation of the waiting times requires
knowledge of the rates, e.g., rTi t ðÞ , at all times t. We therefore
devise a numerical approximation to estimate wi based on the
values of rTi t ðÞ until a given time t, which allows explicit
integration of the dynamical equations (Text S1).
Reverse transcription. To evaluate the probability Qi(jh), we
decouple mutation and recombination [29,32,50]. We let genomes
j and h recombine to produce genome k with probability Rk(jh) and
let genome k mutate to genome i with probability Pik [50]. The
number of different recombinants k that can be produced is 2
d,
where d#n is the number of sites at which j and h differ. Summing
over all the recombinants k gives the total probability of producing
genome i by reverse transcription of genomes j and h,
Qi jh ðÞ ~
X 2d{1
k~0
PikRk jh ðÞ : ð8Þ
Recombination. To determine Rk(jh), we compare genomes j
and h at each of the n drug resistance sites and identify the
distances l1, l2, etc., between the d successive sites at which the
genomes differ (Figure S3). We then compare genome k with the
genomes j and h to determine on which genome, j or h, the enzyme
reverse transcriptase (RT) must be at each of the d distinguishing
sites in order to yield the genome k. Figure S3 illustrates the
desired path of RT for given j, h, and k.I fPdes(m) is the probability
that RT is on the desired genome at the m
th distinctive site, then
Rk jh ðÞ ~ P
d
m~1
Pdes m ðÞ , which is readily evaluated based on the
probabilities that RT undergoes odd and even crossovers in any
length l (Figure S3).
Mutation. To calculate the probability of mutation, Pik,w e
compare the two genomes i and k at the n drug resistance sites and
identify the u sites where the two genomes differ. The probability
that genome k mutates at these u sites alone is Pik~mu 1{m ðÞ
n{u,
where 0#u#n and m is the mutation rate.
Virions.
dVij
dt
~
1
2
1{eij
  
NdTij{cVij ð9aÞ
dVii
dt
~Nd
1{eii ðÞ TizTii ðÞ
z 1
4
P i{1
h~0
1{ehi ðÞ Thi
z
P S
j~iz1
1{eij
  
Tij
0
B B B @
1
C C C A
2
6 6 6 6 6 6 4
3
7 7 7 7 7 7 5
{cVii ð9bÞ
dVNij
dt
~
1
2
eijNdTij{cVNij ð9cÞ
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dt
~Nde ii TizTii ðÞ z
1
4
P i{1
h~0
ehiThi
z
P S
j~iz1
eijTij
0
B B B @
1
C C C A
2
6 6 6 4
3
7 7 7 5
{cVNii ð9dÞ
Here Vii and Vij denote infectious and VNii and VNij non-infectious
virions. In the absence of the drug, cells Ti and Tii produce
homozygous virions Vii and cells Tij produce both homozygous
virions Vii and Vjj and heterozygous virions Vij in the proportion
J, J, and K, respectively [37]. All infected cells with at least one
provirus of type i thus contribute to the production of Vii. N is the
viral burst size, d is the death rate of infected cells and c is the
clearance rate of free virions. The above equations are solved with
the initial condition that the wild type virions V00 alone exist at the
start of the first passage. For every subsequent passage, the free
virions at the end of the previous passage are employed to initiate
infection.
Drug efficacy. The efficacy of a PI is the fraction of progeny
virions that it renders non-infectious. We assume that the drug
efficacy eii against the protease produced by genome i depends on
the number of resistance mutations, m(i), the genome contains, i.e.,
eii=em [23]. We fix the efficacy against the wild type, e0, and that
against the strain with n mutations, en, and determine the efficacies
against intermediate strains from the epistasis, E, which is assumed
constant for every pair of loci differing by two resistance mutations
[27]. If E=0, then the mutations do not interact with each other
and each additional mutation increases the log fitness, which we
define as log(12em), by the same amount (Figure 3). When E,0
(.0), the mutations interact antagonistically (synergistically) in
increasing log fitness. For cells Ti and Tii, the fraction of progeny
virions rendered noninfectious is eii. For cells Tij containing distinct
proviruses, phenotypic mixing [27] implies that proteases i and j
are equally likely to be included in a budding virion so that, on
average, the fraction of virions rendered noninfectious is
eij=(eii+ejj)/2.
When the efficacy is determined as a function of the drug
concentration, C, as in our calculations in Figure 6, we write
eii=C/(IC50(i)+C), where IC50(i) is the value of C at which eii is 50%
[51].
Equations (1) to (9) represent a model of HIV dynamics that
describes the development of resistance to a PI with a genetic
barrier n. We solve the equations using a computer program
written in C.
Model Parameters
We employ the following parameter values based on earlier
studies [4,37,39,52]: the birth and death rate of uninfected T cells,
l=0.624 day
21 and dT=0.018 day
21; the death rate of infected
cells, d=1.44 day
21; the viral burst size, N =10
3; the viral
clearance rate, c=0.35 day
21; the second order rate constants of
the infection of uninfected and singly infected cells,
k0=10
28 day
21 and k1=0.7k0; the mutation and recombination
rates, m=3 610
25 per site per replication, and r=8.3610
24
crossovers per site per replication.
Supporting Information
Figure S1 Model predictions of the times of emergence of
various mutants as the genetic barrier varies from n=2 to 4 and
the epistasis E=20.01 (A) and 0.01 (B). All the other parameters
are identical to those in Figure 4.
Found at: doi:10.1371/journal.pcbi.1000305.s001 (0.06 MB
DOC)
Figure S2 Model predictions of the time of emergence of nth
mutants for different epistatic interactions, E, and genetic barriers
n=3 (A) and n=4 (B). All the other parameters are identical to
those in Figure 4.
Found at: doi:10.1371/journal.pcbi.1000305.s002 (0.06 MB
DOC)
Figure S3 Schematic representation of the production of
genome k by recombination of genomes j and h. Stars indicate
mutations. The arrow marks the desired path of the enzyme
reverse transcriptase (RT) and allows determination of the
probability, Rk(jh), that genome k is formed. At the first site where
j and h differ, the probability that RT is on the desired genome,
Pdes(1), is 1/2, because reverse transcription can commence on
either of the two genomes with equal likelihood. At the second site,
if the desired genome is the same as that of the first site, then RT
will be on the desired genome if it undergoes an even number of
crossovers in the intervening distance l1, the probability of which
we write as Pdes(2)=Peven(l1). If the desired genome is different from
that at the first site, then the probability that RT will be on the
desired genome is Pdes(2)=Podd(l1). It follows that Rk(jh)=PPdes(m),
where m ranges from 1 to d and the probabilities that even and odd
crossovers occur in length l are [37] Peven(l)=exp(2rl)cosh(rl) and
Podd(l)=exp(2rl)sinh(rl), respectively, with r the per site recombi-
nation rate of HIV.
Found at: doi:10.1371/journal.pcbi.1000305.s003 (0.03 MB
DOC)
Table S1 Sequences resistant to tipranavir and their IC50 values.
Sequences with different combinations of resistance mutations
observed experimentally, corresponding binary sequences illus-
trating the specific locations of mutations, marked as 1, when
n=6, and the respective IC50 values employed in our model are
listed. The experimental IC50 values [10] are in brackets. In our
simulations (Figure 6), we assign IC50 values to genomes as follows.
To each genome i, we assign an IC50 value equal to the IC50 of the
genome below that has the maximum number of mutations in
common with the genome i but has no mutations in addition to
those contained in i. For instance, the genome 101001 is assigned
an IC50 of 101 nM, whereas the genome 000110 is assigned an
IC50 of 60 nM, equal to the wild-type.
Found at: doi:10.1371/journal.pcbi.1000305.s004 (0.04 MB
DOC)
Table S2 Drug concentrations employed in the experiments
[10] and in our calculations of Figure 6.
Found at: doi:10.1371/journal.pcbi.1000305.s005 (0.03 MB
DOC)
Text S1 Estimates of waiting times
Found at: doi:10.1371/journal.pcbi.1000305.s006 (0.06 MB
DOC)
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